Scientists weaponize Patients' own cells to hunt down blood cancer
NCT ID NCT07270978
Summary
This early-stage study is testing a new cell therapy for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have detectable cancer cells after initial treatment. Doctors collect a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back into the patient. The main goals are to see if this approach is safe and if it can help clear the remaining cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.